Showing 5421-5430 of 5643 results for "".
- Acucela Initiates Phase 3 Study of Emixustat Addressing Patients with Stargardt Diseasehttps://modernod.com/news/acucela-initiates-phase-3-study-of-emixustat-addressing-patients-with-stargardt-disease/2479674/Acucela announced that on November 7, 2018, the first patient has enrolled in a study to evaluate Acucela’s leading drug candidate, emixustat hydrochloride (emixustat), in subjects with macular atrophy secondary to Stargardt disease. The study is a multicenter, randomized, double-masked, a
- Small-Particle Air Pollution May Raise Glaucoma Risk in Somehttps://modernod.com/news/small-particle-air-pollution-may-raise-glaucoma-risk-in-some/2479675/In people who already have a genetic vulnerability, small-particle air pollution known as black carbon may raise the risk of developing glaucoma, a new study suggests, according to a Reuters report. Researchers found that in older
- Vital Tears Announces the Addition of Mobile Phlebotomy Serviceshttps://modernod.com/news/vital-tears-announces-the-addition-of-mobile-phlebotomy-services/2479692/Vital Tears announced the addition of mobile phlebotomy services to its system of providing autologous serum tears for dry eye therapy. By offering mobile phlebotomy services, patients can now have their blood drawn in the convenience of their own home or office. The addition of a mobile blood dr
- Eye Health America Completes Acquisition of Tampa Bay-Based Updegraff Laser Visionhttps://modernod.com/news/eye-health-america-completes-acquisition-of-tampa-bay-based-updegraff-laser-vision/2479695/Eye Health America (EHA) announced its sixth acquisition of the year, adding Updegraff Laser Vision to its roster of prominent eye care member practices in the Southeast United States. Terms of the deal were not disclosed. The acquisition of the Tampa Bay-based practice continues to
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin
- Oxurion Supporting Prevent Blindness Sight-Saving Programs for Those with Diabeteshttps://modernod.com/news/oxurion-supporting-prevent-blindness-sight-saving-programs-for-those-with-diabetes/2479709/To help support the fight against vision loss and blindness due to diabetes, Oxurion has partnered with Prevent Blindness. During the Diabetic Eye Disease Awareness Month in November, Oxurion will help Prevent Blindness promote awareness and education of the damaging effects that diabetes may hav
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Ophthotech Expands Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4https://modernod.com/news/ophthotech-expands-retinal-disease-pipeline-with-acquisition-of-versant-ventures-inception-4/2479712/Ophthotech Corporation announced that it has acquired Inception 4, a privately held company backed by Versant Ventures, expanding Ophthotech’s therapeutic pipeline in age-related retinal indications. Through this acquisition, Ophthotech gains worldwide development and commercialization rig
- AAO: Unapproved Therapies Cause Significantly More Patient Injuries Than Reported by Cell Therapy Clinicshttps://modernod.com/news/aao-unapproved-therapies-cause-significantly-more-patient-injuries-than-reported-by-cell-therapy-clinics/2479716/A team of ophthalmologists went looking for scientific evidence in support of commercially available “cell therapy” for eye diseases. Not only did they find virtually none, they discovered a growing number of patients are being irreparably harmed by unapproved cell therapies, accordin